Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Search Results for "Rituximab Patent"

08:21 EDT 28th July 2014 | BioPortfolio

Matching Channels

CD20 Antibodies

The chimeric anti-CD20 antibody rituximab (Rituxan & MabThera) from Biogen Idec and Genentech/Roche is one of the world’s commercially most successful antibodies (2007 sales of over US$ 5 bl...

Biosuperior Antibodies

After biosimilar versions of therapeutic proteins have become reality in Europe and in the US, now it’s the turn of therapeutic antibodies to be in the line of fire. Patents of the first wave of...


India, in the Asian subcontinent is the world’s fourth largest producer of pharmaceuticals, and is thought as one of the most promising biotech markets in the world. Several important steps...

Drug Delivery - news, views, blogs

Drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in humans or animals.  Drug delivery technologies are patent protected formulat...

Tumor Necrosis Factor TNF Products

Tumor Necrosis Factor (TNF) and TNF receptor antagonists and agonists used to treat TNF-mediated inflammatory diseases such as rheumatoid arthritis or to treat cancer. TNF blockers are the commerc...

Matching News

Combination of Idelalisib and Rituximab Improves Survival in Patients with Relapsed Chronic Lymphocytic Leukemia

In an international randomized double-blind phase III clinical trial, patients with relapsed chronic lymphocytic leukemia (CLL) who received the investigational drug idelalisib in combination with rit...

[Comment] Subcutaneous rituximab: a practical approach?

Rituximab, a chimeric anti-CD20 monoclonal antibody, has improved the therapeutic outcomes of patients with B-cell non-Hodgkin lymphoma of various histopathological subtypes and B-cell chronic lymphoc...

Biosimilar rituximab approved in Russia

Russian biotechnology company Biocad announced on 17 April 2014 that the Russian Ministry of Health has approved the company’s biosimilar rituximab drug, AcellBia (BCD-20). The drug is a biosimilar...

[Articles] Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study

Stage 1 data show that the pharmacokinetic profile of subcutaneous rituximab was non-inferior to intravenous rituximab and was not associated with new safety concerns. Stage 2 will provide data for ef...

Biocad's rituximab biosimilar approved in Russia

Biocad (St. Petersburg, Russia) said the Russian Ministry of Health approved the company's AcellBia (BCD-20), a biosimilar of autoimmune and cancer drug rituximab. Biocad said AcellBia is the first mA...

Obinutuzumab Beats Rituximab in CLL

Progression-free survival was longer when obinutuzumab was added to chemotherapy than when rituximab was added for patients with chronic lymphocytic leukemia (CLL) and comorbidities. Medscape Medica...

Rituximab Inactivates Graves' Orbitopathy, New Data Show

Patients with Graves' orbitopathy showed disease inactivation after a single 500-mg dose of rituximab that was maintained at 6 months' assessment. Medscape Medical News

Rituximab and Survival in Burkitt Lymphoma

How effective is the addition of rituximab to chemotherapy in patients with Burkitt lymphoma? Therapeutic Advances in Hematology

Matching PubMed Articles

Patent highlights.

A snapshot of recent key developments in the patent literature of relevance to the advancement of pharmaceutical and medical R&D.

Patent quality.

Against a backdrop of a rising generics market and increasing patent expiries, the 'quality' of patents has become an ever more significant topic of debate. Pharmaceutical Patent Analyst has brought t...

Patenting time-lapse microscopy: the European story.

European Patent No. 2430454 of Stanford University is open to opposition before the European Patent Office if such opposition is filed by 23 October 2013. This is the European equivalent of the US Pat...

Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy.

To evaluate the efficacy and safety of two different targeted approaches-abatacept or tocilizumab-after rituximab therapy in rheumatoid arthritis, and to explain observed difference in efficacy using...

Late-onset neutropenia and acute rejection in ABO-incompatible kidney transplant recipients receiving rituximab and mycophenolate mofetil.

Using rituximab, we have performed successful ABO-incompatible kidney transplantations in recipients without splenectomy as well as in those with high pretransplant anti-A/B antibody titers. A common...

Search Whole site using Google

Search BioPortfolio:
Advertisement Advertisement